MX2009004748A - Interaccion orientada nbs1-atm para sensibilizar celulas cancerosas a radioterapia y quimioterapia. - Google Patents

Interaccion orientada nbs1-atm para sensibilizar celulas cancerosas a radioterapia y quimioterapia.

Info

Publication number
MX2009004748A
MX2009004748A MX2009004748A MX2009004748A MX2009004748A MX 2009004748 A MX2009004748 A MX 2009004748A MX 2009004748 A MX2009004748 A MX 2009004748A MX 2009004748 A MX2009004748 A MX 2009004748A MX 2009004748 A MX2009004748 A MX 2009004748A
Authority
MX
Mexico
Prior art keywords
chemotherapy
cancer cells
nbs1
radiotherapy
targeting
Prior art date
Application number
MX2009004748A
Other languages
English (en)
Spanish (es)
Inventor
Bo Xu
Mickael J Cariveau
Original Assignee
Southern Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Res Inst filed Critical Southern Res Inst
Publication of MX2009004748A publication Critical patent/MX2009004748A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/43—Sweetening agents, e.g. thaumatin, monellin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2009004748A 2006-10-30 2007-10-30 Interaccion orientada nbs1-atm para sensibilizar celulas cancerosas a radioterapia y quimioterapia. MX2009004748A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86345706P 2006-10-30 2006-10-30
PCT/US2007/022886 WO2008054726A2 (en) 2006-10-30 2007-10-30 Targeting nbs1-atm interaction to sensitize cancer cells to radiotherapy and chemotherapy

Publications (1)

Publication Number Publication Date
MX2009004748A true MX2009004748A (es) 2009-08-25

Family

ID=39344878

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004748A MX2009004748A (es) 2006-10-30 2007-10-30 Interaccion orientada nbs1-atm para sensibilizar celulas cancerosas a radioterapia y quimioterapia.

Country Status (9)

Country Link
US (1) US20100120679A1 (enExample)
EP (1) EP2091964A2 (enExample)
JP (1) JP2010508022A (enExample)
KR (1) KR20090102744A (enExample)
CN (1) CN101631799A (enExample)
AU (1) AU2007314366A1 (enExample)
CA (1) CA2674238A1 (enExample)
MX (1) MX2009004748A (enExample)
WO (1) WO2008054726A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8118754B1 (en) 2007-11-15 2012-02-21 Flynn Edward R Magnetic needle biopsy
US9964469B2 (en) 2005-02-28 2018-05-08 Imagion Biosystems, Inc. Magnetic needle separation and optical monitoring
US8841414B1 (en) * 2006-01-27 2014-09-23 University Of Mississippi Medical Center Targeted delivery of therapeutic peptides by thermally responsive biopolymers
US8447379B2 (en) 2006-11-16 2013-05-21 Senior Scientific, LLC Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof
KR20120087165A (ko) 2009-11-06 2012-08-06 사이언티픽 나노메디슨, 아이엔씨. 표적화된 나노입자 및 그것의 자기 특성을 사용하는 암 및 다른 생물학적 물질과 같은 세포의 검출, 측정 및 이미징
US10194825B2 (en) 2009-11-06 2019-02-05 Imagion Biosystems Inc. Methods and apparatuses for the localization and treatment of disease such as cancer
EP2702172B1 (en) * 2011-04-29 2020-01-01 Aarhus Universitet Method for determining clinically relevant hypoxia in cancer
EP2797617B1 (en) * 2011-12-27 2020-01-22 Sorbonne Université Anti-tumor adjuvant therapy
GB201209517D0 (en) * 2012-05-29 2012-07-11 Univ Birmingham Nanoparticles
CN104046644A (zh) * 2013-03-14 2014-09-17 中国科学院上海生命科学研究院 人源化小鼠模型的构建方法和应用
KR101447901B1 (ko) * 2013-04-16 2014-10-16 한양대학교 산학협력단 지방세포 표적 비바이러스성 유전자 전달체
EP3110504B1 (en) * 2014-02-27 2018-12-26 Koninklijke Philips N.V. Medical instrument for high dose rate brachytherapy
WO2017004136A1 (en) 2015-06-30 2017-01-05 Tela Bio, Inc. Corner-lock stitch patterns
WO2017015421A1 (en) 2015-07-21 2017-01-26 Tela Bio, Inc. Compliance control stitching in substrate materials
WO2017189772A1 (en) 2016-04-26 2017-11-02 Tela Bio, Inc. Hernia repair grafts having anti-adhesion barriers
KR101875111B1 (ko) * 2016-04-29 2018-07-09 한국수력원자력 주식회사 저선량 방사선을 이용한 암화유전자 Ras-유도 악성 암화 억제
BR112019017087A2 (pt) * 2017-02-16 2020-04-14 Firststring Res Inc composição e métodos para prevenir a lesão por radiação e promover a regeneração do tecido.
WO2018195434A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
WO2018195446A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
WO2018213764A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
US11160821B2 (en) 2017-05-19 2021-11-02 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
CU20190106A7 (es) 2017-06-26 2020-11-30 Lunella Biotech Inc Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas
EP3761963B1 (en) 2018-03-09 2025-01-22 Tela Bio, Inc. Surgical repair graft
US11446130B2 (en) 2019-03-08 2022-09-20 Tela Bio, Inc. Textured medical textiles
WO2023069094A1 (en) * 2021-10-20 2023-04-27 Castor Trevor P Method and apparatus for inactivating pathogens in units of whole blood using superparamagnetic nanoparticles coated with chemiluminescence reagents and broad-spectrum anti-viral therapeutics
CN115300449B (zh) * 2022-02-07 2023-06-27 郑州大学第一附属医院 榄香烯在制备抑制肿瘤耐药性的控释制剂中的应用
CN118126155B (zh) * 2024-02-05 2025-04-25 中山大学附属第七医院(深圳) 一种人nbs1蛋白赖氨酸388位点乳酸化抗原、抗体及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077880A (en) * 1997-08-08 2000-06-20 Cordis Corporation Highly radiopaque polyolefins and method for making the same
US7074902B1 (en) * 1998-04-27 2006-07-11 Warf Wisconsin Alumni Research Foundation Antibody specific for a DNA repair protein
US7122343B1 (en) * 1998-04-27 2006-10-17 Wisconsin Alumni Research Foundation Methods to alter levels of a DNA repair protein
US6530944B2 (en) * 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US20030104427A1 (en) * 2001-06-25 2003-06-05 Petrini John H.J. Methods to modulate telomere structure and function

Also Published As

Publication number Publication date
JP2010508022A (ja) 2010-03-18
EP2091964A2 (en) 2009-08-26
US20100120679A1 (en) 2010-05-13
WO2008054726A2 (en) 2008-05-08
CN101631799A (zh) 2010-01-20
KR20090102744A (ko) 2009-09-30
WO2008054726A3 (en) 2009-02-05
CA2674238A1 (en) 2008-05-08
AU2007314366A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
WO2008054726A3 (en) Targeting nbs1-atm interaction to sensitize cancer cells to radiotherapy and chemotherapy
NZ608142A (en) Amatoxin-conjugates with improved linkers
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
EP4501352A3 (en) Compositions and methods for car t cell therapy
EA201391351A1 (ru) Способы повышения эффективности folr1 терапии рака
MX2010008817A (es) Tratamiento de cancer de prostata en etapa metastatica con degarelix.
MX344009B (es) Conjugados de amatoxinas con enlaces mejorados.
PT1890732T (pt) Preparações vasoconstritoras tópicas e processos destinados a proteger as células durante quimioterapia e radioterapia anticancerosas
EA201390642A1 (ru) Цитотоксические агенты, содержащие новые производные анзамитоцина
MY160399A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
CR20110553A (es) Terapia complementaria contra el cáncer
IL207310A0 (en) Vaccine compositions
EP2081590A4 (en) Cancer stem cell-targeted cancer therapy
AU2012335543A8 (en) HER3 antibodies and uses thereof
MX2010005095A (es) Moduladores novedosos de puntos de verificación del ciclo celular y su uso en combinacion con inhibidores de cinasa de puntos de verificacion.
WO2012047317A3 (en) Tumor specific antibodies and uses therefor
MX2013015340A (es) Composiciones y metodos para el tratamiento de cancer.
WO2010030365A3 (en) Thyroid tumors identified
IN2014DN11205A (enExample)
IN2012DN02046A (enExample)
MX2012000575A (es) Conjugados de epsilon-polilisina y uso de los mismos.
TW200744568A (en) Epinephrine dosing regimens
JO2833B1 (en) Amino pyrazole compound
MX2011011596A (es) Perifosina y capecitabina como un tratamiento combinado para cancer.
MX364002B (es) Compuestos y composiciones activadoras de enzima.

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal